Remdesivir currently has emergency status application for hospital use, the DEP version has the potential to expand the application outside of hospital and may prove more effective and less toxic. This would be extremely valuable for Gilead the drug would have a much bigger market.
There has to be more news about the next step of development.
Ann: SPL creates slow release soluble DEP remdesivir nanoparticle, page-83
-
- There are more pages in this discussion • 124 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.2¢ |
Change
-0.001(1.08%) |
Mkt cap ! $38.39M | |||
| Open | High | Low | Value | Volume |
| 9.2¢ | 9.3¢ | 9.1¢ | $210.6K | 2.290M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 467139 | 9.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.4¢ | 152000 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| SPL (ASX) Chart |